Mersana Presents New Data On Investigational Cancer Antibody Drug Conjugate At AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Fleximer® platform technology, today announced that it will present data on its lead preclinical immunoconjugate, XMT-1522, at the American Association of Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. The two poster presentations will highlight results from ongoing non-clinical studies where the compound was evaluated as a potential combination partner with immunomodulatory cancer therapies and it was also characterized for its pharmacokinetics, metabolism and biodistribution in tumor-bearing mice.

The accepted abstracts are listed below and are now available online on the AACR 2017 conference website: www.aacr.org

Abstract Control Number: 6879
Title: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models
Authors: Natasha Bodyak, Marina Protopopova, Qingxiu Zhang, Alex Yurkovetskiy, Mao Yin, LiuLiang Qin, Laura L Poling, Rebecca Mosher, Donald A. Bergstrom, Timothy B. Lowinger
Session Category: Immunology
Session Title: Immune Response to Hematopoietic Tumors: New Developments in Tumor Immunology
Session Date and Time: Monday Apr 3, 2017 1:00 PM - 5:00 PM
Location: Convention Center, Halls A-C, Poster Section 26
Poster Board Number: 29

Abstract control number: 6716
Title: Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate.
Authors: Donald A. Bergstrom, Natalya Bodyak, Alex Yurkovetskiy, Michael DeVit, Mao Yin, Laura L. Poling, Joshua D. Thomas, Dmitry Gumerov, Dongmei Xiao, Elena Ter-Ovanesyan, Charlie Bu, LiuLiang Qin, Alex Uttard, Alex Johnson, Timothy B. Lowinger
Session Category: Experimental and Molecular Therapeutics
Session Date and Time: Sunday Apr 2, 2017 1:00 PM - 5:00 PM
Location: Convention Center, Halls A-C, Poster Section 26
Poster Board Number: 29

About XMT-1522

XMT-1522 incorporates a novel, proprietary HER2 antibody, which is conjugated with Mersana’s Dolaflexin platform which includes its Fleximer technology and proprietary auristatin payload. XMT-1522 provides a drug load of approximately 12-15 molecules per antibody, specifically designed to improve potency while simultaneously increasing tolerability. XMT-1522 has the potential to extend HER2-targeted therapy beyond the current “HER2-positive” populations into patients with lower levels of HER2 expression.

About Mersana Therapeutics

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms provide for expanded opportunities to provide meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.